Skip to content

Study · Systematic review · 2023

4 results

The efficacy of thymosin alpha-1 therapy in moderate to critical COVID-19 patients: a systematic review, meta-analysis, and meta-regression.

Soeroto AY, Suryadinata H, Yanto TA, Hariyanto TI

Inflammopharmacology16 Oct 2023Cited by 2 (Europe PMC)

PMID37845598 (opens in a new tab)DOI10.1007/s10787-023-01354-2 (opens in a new tab)PepBankPUB-37845598
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In patients with moderate to critical COVID-19, thymosin alpha‑1 therapy was associated with significantly lower mortality than placebo in pooled data.

    In plain wordsIn people with moderate to critical COVID-19, thymosin alpha‑1 was linked to fewer deaths than placebo in pooled studies.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseMortality from COVID-19
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Mortality · Infection
    Studied dose
    Dose not stated

    Measurements

    RR
    0.59 ratio
    mortality

    Source sentences

    Summary
    significantly lower mortality from COVID-19 (RR 0.59; 95% CI 0.37-0.93, p = 0.02, I2 = 84%)
  2. 02HumanSystematic reviewEfficacy outcome

    In patients with moderate to critical COVID-19, thymosin alpha‑1 therapy showed no difference in the need for mechanical ventilation compared with placebo.

    In plain wordsIn people with moderate to critical COVID-19, thymosin alpha‑1 did not change the need for a ventilator compared with placebo.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeNeed for mechanical ventilation
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Respiratory function · Respiratory
    Studied dose
    Dose not stated

    Measurements

    RR
    0.83 ratio
    mechanical ventilation

    Source sentences

    Summary
    mechanical ventilation (RR 0.83; 95% CI 0.48-1.44, p = 0.51, I2 = 74%)
  3. 03HumanSystematic reviewEfficacy outcome

    In patients with moderate to critical COVID-19, thymosin alpha‑1 therapy showed no difference in hospital length of stay compared with placebo.

    In plain wordsIn people with moderate to critical COVID-19, thymosin alpha‑1 did not change hospital stay length compared with placebo.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeHospital length of stay
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Intensive care and hospital outcomes · Whole body
    Studied dose
    Dose not stated

    Measurements

    MD
    2.32
    hospital length of stay

    Source sentences

    Summary
    hospital length of stay (MD 2.32; 95% CI - 0.93, 5.58, p = 0.16, I2 = 94%) compared to placebo.
  4. 04HumanSystematic reviewOther

    In patients with moderate to critical COVID-19, the mortality benefit of thymosin alpha‑1 was significantly affected only by sample size and sex in meta-regression.

    In plain wordsIn pooled studies of moderate to critical COVID-19, the link between thymosin alpha‑1 and fewer deaths differed only by study size and by sex.

    Peptide
    Thymosin alpha-1
    Outcome
    Not applicableModerators of the mortality benefit (meta-regression)
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Mortality · Infection
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The benefits of thymosin alpha-1 on the mortality rate were significantly affected only by sample size (p = 0.0000) and sex (p = 0.0117).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.